This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
2024 Circulation Myocardial Infarction 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4141714-A4141714, November 12, 2024. Background:Myocardial infarction is a leading cause of morbidity and mortality worldwide, often resulting in extensive myocardial cell death and the release of damage-associated molecular patterns.
Circulation
NOVEMBER 24, 2024
Circulation, Volume 150, Issue 22 , Page 1812-1814, November 26, 2024.
Circulation
SEPTEMBER 8, 2024
Circulation, Volume 150, Issue 11 , Page 836-837, September 10, 2024.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4146832-A4146832, November 12, 2024. Introduction:After a myocardial infarction (MI), cardiac fibroblasts are activated to deposit extracellular matrix that while prevents acute cardiac rupture in the short-term, causes long-term diastolic and systolic dysfunction.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4135229-A4135229, November 12, 2024. eGC shedding could contribute to atherosclerotic plaque vulnerability and acute myocardial infarction (AMI) installation.
Cardiology Update
APRIL 9, 2024
The American College of Cardiology (ACC) held its 73 rd annual scientific session and expo April 6-8, 2024 in Atlanta, Georgia. EMPACT-MI 1 ( NCT04509674 ) studied the effects of empagliflozin in patients who have experienced myocardial infarction (MI). April 6, 2024. April 7, 2024. April 7, 2024.
52 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4141170-A4141170, November 12, 2024. In cardiovascular research, serotonin has been implicated in modulating vascular tone, platelet aggregation, and myocardial function. years, 53 women) followed for up to 15 years.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4139191-A4139191, November 12, 2024. These challenges highlight the need for new therapies that are both safe and effective in targeting the structural remodeling pivotal to disease progression post-myocardial infarction (MI).
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4135252-A4135252, November 12, 2024. Background:Pulmonary hypertension (PH) is a major contributor to cardiovascular disease-related morbidity and mortality.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4121215-A4121215, November 12, 2024. Heterogeneity was examined with I2statistics.Results:We included 12 RCT articles consisting of 23,178 patients that received empagliflozin after acute myocardial infarction were considered.
Circulation: Cardiovascular Interventions
DECEMBER 16, 2024
Circulation: Cardiovascular Interventions, Volume 17, Issue 12 , Page e014890, December 1, 2024.
Circulation
JANUARY 21, 2024
Circulation, Volume 149, Issue 4 , Page 335-338, January 23, 2024.
Circulation
JANUARY 7, 2024
Circulation, Volume 149, Issue 2 , Page 167-167, January 9, 2024.
Circulation
MARCH 17, 2024
Circulation, Volume 149, Issue 12 , Page e962-e963, March 19, 2024.
DAIC
MAY 8, 2024
2024, [link]. Circulation, vol. 1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronary artery disease (CAD), historically linked with a mortality rate exceeding 50 percent within five years. The Lancet, vol.
Dr. Smith's ECG Blog
SEPTEMBER 18, 2024
Thus, it has recently become generally accepted that most plaque ruptures resulting in myocardial infarction occur in plaques that narrow the lumen diameter by 40% of the arterial cross section may be involved by plaque. This confirms that the pain was ischemia and is now resovled. The i nitial hs troponin I returned 75%.
121 Circulation
JANUARY 7, 2024
Circulation, Volume 149, Issue 2 , Page 168-169, January 9, 2024.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4132742-A4132742, November 12, 2024. However, FFR-guided CR showed no beneficial effect on all-cause mortality, stroke, major bleeding and myocardial infarction. The pooled results of the 4 RCTs showed that MACE (RR=0.66; 95% CI [0.45, 0.99]; p=0.01; 16.8%
DAIC
APRIL 30, 2024
Image courtesy of Hideki Kobayashi from Shinshu University milla1cf Tue, 04/30/2024 - 12:53 April 30, 2024 — Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart to recover lost function. However, the risk of arrhythmias following this procedure is reportedly high.
105 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4139285-A4139285, November 12, 2024. Introduction:Stroke and Myocardial Infarction (MI) are the leading causes of death in the United States. Awareness of symptoms is vital for early recognition and prompt treatment, which can significantly improve health outcomes.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4121234-A4121234, November 12, 2024. Background:Ischemia-related ventricular arrhythmia is the leading cause of death in patients after acute myocardial infarction (AMI).
Circulation
MARCH 3, 2024
Circulation, Volume 149, Issue 10 , Page 732-733, March 5, 2024.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4141868-A4141868, November 12, 2024. Inflammatory responses result from coordinated actions of circulating molecular mediators and circulating immune cells (CIC). The complete blood count (CBC) is the standard approach to profile CIC.
40 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4144918-A4144918, November 12, 2024. Background:The adverse effects of iron deficiency (ID) on left ventricular function and outcomes in patients with acute coronary syndrome have been established.
Circulation
NOVEMBER 10, 2024
Circulation, Volume 150, Issue 20 , Page e444-e444, November 12, 2024.
Circulation
FEBRUARY 25, 2024
Circulation, Volume 149, Issue 9 , Page 725-726, February 27, 2024.
Dr. Smith's ECG Blog
OCTOBER 8, 2024
Given that this is before it is released into the circulation by reperfusion therapy, this is a massively elevated troponin. Hyperacute T Wave in the Early Diagnosis of Acute Myocardial Infarction. Interpretation of acute myocardial infarction with persistent “hyperacute T waves” by cardiac magnetic resonance.
122 
Dr. Smith's ECG Blog
SEPTEMBER 5, 2024
This is a value typical for a large subacute MI, n ormal value 48 hours after myocardial infarction is associated with Post-Infarction Regional Pericarditis ( PIRP ). Mechanical complications secondary to myocardial infarction are infrequent due to most patients receiving revascularization quite rapidly.
Circulation
FEBRUARY 25, 2024
Circulation, Volume 149, Issue 9 , Page 727-728, February 27, 2024.
DAIC
JANUARY 25, 2024
Getty Images milla1cf Thu, 01/25/2024 - 20:44 January 25, 2024 — Agepha Pharma , a leading multinational pharmaceutical company with the first FDA-approved anti-inflammatory cardiovascular treatment ( LODOCO – colchicine, 0.5 In June 2023, the U.S.
110 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4129945-A4129945, November 12, 2024. Objectives:The aim of this study was to assess the risk of stroke for temporary mechanical circulatory support (tMCS) device treated acute myocardial infarction (AMI).Background:Data 2.00]), and atrial fibrillation (aOR 1.34, 95%CI [1.31-1.38]).
40 Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4137359-A4137359, November 12, 2024. The primary endpoint was composite (cardiovascular death, myocardial infarction, stroke), and the secondary endpoints were myocardial infarction and stroke. Results:The mean follow-up period was 53 ± 17 months.
40 
DAIC
MARCH 28, 2024
milla1cf Thu, 03/28/2024 - 07:28 March 28, 2024 — Biosense Webster, Inc., patients, were presented as a late-breaker at the 2024 AF Symposium. In Europe, the TRUPULSE generator received CE mark in late 2023 and the VARIPULSE Catheter received CE mark in February 2024. Circulation Research. PMID: 31955707.
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4143007-A4143007, November 12, 2024. Background:Myocardial infarction with nonobstructive coronary artery disease (MINOCA) is a special syndrome with clear evidence of myocardial ischemia, but no clear stenosis of coronary artery imaging sign.
Dr. Smith's ECG Blog
AUGUST 9, 2024
AIVR is not always the result of significant pathology, but is classically associated with the reperfusion phase of acute myocardial infarction. Similarly, the OMI paradigm respects ACS as a dynamic process in which ECG changes reflect the phase of myocardial injury and risk stratify which patients may benefit from emergent PCI.
107 
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4113411-A4113411, November 12, 2024. The primary outcome was a composite of the incidence of myocardial infarction and ischemic and hemorrhagic stroke, obtained by tracking the medical use data of the first-ever ICD-10 codes. years and median follow-up duration was 15.9
Circulation: Cardiovascular Interventions
MARCH 30, 2025
Circulation: Cardiovascular Interventions, Ahead of Print. Endpoints included major adverse cardiovascular events (MACE), cardiac death, myocardial infarction (MI), periprocedural MI, all-cause mortality, stent thrombosis (definite or probable), and target vessel revascularization (TVR).
40 
Dr. Smith's ECG Blog
APRIL 18, 2024
Circulation 2014 2. Int J Cardiol 2024 3. Immediate and early percutaneous coronary intervention in very high-risk and high-risk non-ST segment elevation myocardial infarction patients. Eur Heart J Digital Health 2024 5. Amsterdam et al. Alencar et al. Lupu et al. Clin Cardiol 2022 4. McLaren and Smith.
121 Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4142612-A4142612, November 12, 2024. The primary endpoint was 5-year MACCE, defined as a composite of all-cause mortality, myocardial infarction, and stroke. This trend was consistent for 5-year all-cause mortality, myocardial infarction, and stroke.
DAIC
JANUARY 23, 2024
3 Patients with ASCVD are at a higher risk for major adverse cardiovascular events (MACE) including heart attack or myocardial infarction (MI), stroke, and cardiovascular (CV) death.4 2019 Sep 10;140(11):e649-e650] [published correction appears in Circulation. 2020 Jan 28;141(4):e60] [published correction appears in Circulation.
Circulation: Cardiovascular Interventions
FEBRUARY 27, 2024
Circulation: Cardiovascular Interventions, Ahead of Print. Cardiogenic shock and acute ST-segment–elevation myocardial infarction are exclusions. INTRODUCTION:Percutaneous coronary intervention for complex coronary disease is associated with a high risk of cardiogenic shock.
Circulation: Cardiovascular Quality & Outcomes
NOVEMBER 20, 2024
Circulation: Cardiovascular Quality and Outcomes, Volume 17, Issue 12 , Page e011040, December 1, 2024. Secondary end points included cardiovascular death and nonfatal myocardial infarction with and without hospitalization for heart failure. Participants were followed up for a median time of 4.9
Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4148106-A4148106, November 12, 2024. Background:Hemophilia is a rare X-linked recessive inherited bleeding disorder. The primary outcome was to estimate the prevalence of cardiovascular risk factors in patients with hemophilia compared to the general population.
40 Circulation
NOVEMBER 11, 2024
Circulation, Volume 150, Issue Suppl_1 , Page A4145554-A4145554, November 12, 2024. Adverse CVD outcomes was defined as a composite of incident heart failure, incident atrial fibrillation / flutter, incident myocardial infarction or all-cause mortality. OSA also increased the risk of ischemic stroke.
40
Expert insights. Personalized for you.
We have resent the email to
Are you sure you want to cancel your subscriptions?
Let's personalize your content